+

AU2001268680A1 - Methods and compositions for the treatment of peripheral artery disease - Google Patents

Methods and compositions for the treatment of peripheral artery disease

Info

Publication number
AU2001268680A1
AU2001268680A1 AU2001268680A AU6868001A AU2001268680A1 AU 2001268680 A1 AU2001268680 A1 AU 2001268680A1 AU 2001268680 A AU2001268680 A AU 2001268680A AU 6868001 A AU6868001 A AU 6868001A AU 2001268680 A1 AU2001268680 A1 AU 2001268680A1
Authority
AU
Australia
Prior art keywords
artery disease
fgf
peripheral artery
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268680A
Inventor
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001268680A1 publication Critical patent/AU2001268680A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.
AU2001268680A 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease Abandoned AU2001268680A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US21350400P 2000-06-22 2000-06-22
US60/213,504 2000-06-22
US26457201P 2001-01-26 2001-01-26
US60/264,572 2001-01-26
US27654901P 2001-03-16 2001-03-16
US60/276,549 2001-03-16
US09/886,856 US20020115603A1 (en) 2000-06-22 2001-06-21 Methods and compositions for the treatment of peripheral artery disease
US09/886,856 2001-06-21
PCT/US2001/019978 WO2001098346A2 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease

Publications (1)

Publication Number Publication Date
AU2001268680A1 true AU2001268680A1 (en) 2002-01-02

Family

ID=27498936

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268680A Abandoned AU2001268680A1 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease

Country Status (8)

Country Link
US (3) US20020115603A1 (en)
EP (1) EP1324766B1 (en)
JP (1) JP2004501164A (en)
AT (1) ATE383168T1 (en)
AU (1) AU2001268680A1 (en)
CA (1) CA2414020A1 (en)
DE (1) DE60132343T2 (en)
WO (1) WO2001098346A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
US20030004753A1 (en) * 2001-06-27 2003-01-02 Blackshear William M. Management method of persons at risk of complications of arterial occlusive disease
EP1492559A4 (en) * 2002-04-08 2005-07-27 Scripps Research Inst TRUNKED 24 KDA BASIC FIBROBLAST GROWTH FACTOR
JP4532092B2 (en) * 2003-09-30 2010-08-25 泰彦 田畑 Angiogenic agent
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
CA2611856C (en) * 2005-06-29 2018-02-27 Mars, Incorporated Inducing peripheral blood vessel vasodilation using polyphenols provided as cocoa
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US8812123B2 (en) * 2007-10-17 2014-08-19 Intelect Medical, Inc. Patient programmer with input and sensing capabilities
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
SI2842573T1 (en) 2008-11-07 2018-01-31 Galaxy Biotech, Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2011025865A1 (en) 2009-08-27 2011-03-03 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
AU2011267853B2 (en) 2010-06-14 2016-12-08 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
JP6005723B2 (en) 2011-03-29 2016-10-12 ボストン サイエンティフィック ニューロモデュレイション コーポレイション System and method for image registration
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
CA2844081A1 (en) 2011-08-09 2013-02-14 Boston Scientific Neuromodulation Corporation Remote control for blind clinical trials of electrical stimulation
US9604067B2 (en) 2012-08-04 2017-03-28 Boston Scientific Neuromodulation Corporation Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices
JP6224106B2 (en) 2012-08-28 2017-11-01 ボストン サイエンティフィック ニューロモデュレイション コーポレイション Capture and visualize clinical effect data for leads and / or stimulus centers
WO2014070290A2 (en) 2012-11-01 2014-05-08 Boston Scientific Neuromodulation Corporation Systems and methods for voa model generation and use
US9308000B2 (en) 2013-07-12 2016-04-12 Vasoinnovations, Inc. Method of transradial catheterization, device for ulnar artery compression, and method of use
US11564697B2 (en) 2013-07-12 2023-01-31 Vasoinnovations Inc. Apparatus and method to stop bleeding
US10342551B2 (en) 2013-07-12 2019-07-09 Vasoinnovations Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10888334B2 (en) 2013-07-12 2021-01-12 Vasoinnovations Inc. Apparatus and method to stop bleeding
US9949738B2 (en) * 2013-07-12 2018-04-24 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US9332994B2 (en) 2013-07-12 2016-05-10 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US10213214B2 (en) * 2013-07-12 2019-02-26 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US20230018664A1 (en) * 2013-07-12 2023-01-19 Vasoinnovations, Inc. Method to stop bleeding after a catheterization procedure using a large bore sheath
US9668744B2 (en) 2015-08-05 2017-06-06 Vasoinnovations, Inc. Apparatus and method to stop bleeding
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
EP3204112A1 (en) 2014-10-07 2017-08-16 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
WO2016191436A1 (en) 2015-05-26 2016-12-01 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
EP3280490B1 (en) 2015-06-29 2021-09-01 Boston Scientific Neuromodulation Corporation Systems for selecting stimulation parameters based on stimulation target region, effects, or side effects
ES2940303T3 (en) 2015-06-29 2023-05-05 Boston Scient Neuromodulation Corp Stimulation parameter selection systems by use of targets and direction
WO2017062378A1 (en) 2015-10-09 2017-04-13 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulations leads
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
US10776456B2 (en) 2016-06-24 2020-09-15 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
WO2018044881A1 (en) 2016-09-02 2018-03-08 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
EP3493876B1 (en) 2016-10-14 2021-03-17 Boston Scientific Neuromodulation Corporation Systems for closed-loop determination of stimulation parameter settings for an electrical simulation system
US10792501B2 (en) 2017-01-03 2020-10-06 Boston Scientific Neuromodulation Corporation Systems and methods for selecting MRI-compatible stimulation parameters
US10589104B2 (en) 2017-01-10 2020-03-17 Boston Scientific Neuromodulation Corporation Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
US11357986B2 (en) 2017-04-03 2022-06-14 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
EP3615560B1 (en) * 2017-04-26 2025-03-05 University of Cincinnati Fibroblast growth factor for use in treating patients unergoing ischemia-reperfusion therapy
WO2019014224A1 (en) 2017-07-14 2019-01-17 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
EP3634569A1 (en) 2017-08-15 2020-04-15 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
CN112041022B (en) 2018-04-27 2024-07-02 波士顿科学神经调制公司 Multi-mode electrical stimulation system and methods of making and using the same
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604293A (en) * 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
ES2155534T3 (en) * 1994-10-12 2001-05-16 Focal Inc ADMINISTRATION DIRECTED THROUGH BIODEGRADABLE POLYMERS.
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5941868A (en) * 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
JP5329729B2 (en) * 1998-09-03 2013-10-30 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Unit dose FGF-2 effective for angiogenesis and methods of use
SE9802974D0 (en) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
WO2000021548A2 (en) 1998-10-13 2000-04-20 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease

Also Published As

Publication number Publication date
US20070135348A1 (en) 2007-06-14
ATE383168T1 (en) 2008-01-15
DE60132343D1 (en) 2008-02-21
EP1324766B1 (en) 2008-01-09
US20020115603A1 (en) 2002-08-22
JP2004501164A (en) 2004-01-15
EP1324766A2 (en) 2003-07-09
CA2414020A1 (en) 2001-12-27
WO2001098346A2 (en) 2001-12-27
WO2001098346A3 (en) 2003-05-01
US7186407B2 (en) 2007-03-06
DE60132343T2 (en) 2008-12-24
US7541337B2 (en) 2009-06-02
US20040209817A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
AU2001268680A1 (en) Methods and compositions for the treatment of peripheral artery disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
AU6762794A (en) A coagulation factor viii formulation
ATE307608T1 (en) COMBINATION OF DOCTAXEL AND RHUMAB HER2 FOR CANCER TREATMENT
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL208184A0 (en) Glp-1, and methods for treating diabetes
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
EP1201246A3 (en) Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia
BR9813318A (en) Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
ATE279937T1 (en) FGF-2 ANGIOGENIC EFFECTIVE UNIT DOSE AND ITS USE
EP1894570A3 (en) Methods and compositions for the treatment of peripheral artery disease
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
KR101255200B1 (en) Combination of egf/ghrp-6 for the neuroregeneration of the central nervous system following autoimmune damage
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
CA2336773A1 (en) Component b as angiogenic agent in combination with human growth factors
RU2130773C1 (en) Method for treating the cases of kaposi sarcoma
RU2140270C1 (en) Method of treatment of patient with kaposi's sarcoma idiopathic type
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
Zhyl'chuk Increasing the efficacy of treating patients with extensive ovarian cancer by using laferon
RU2002122380A (en) A method for the treatment of patients with disseminated forms of prostate cancer
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载